Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPLASH trial of stereotactic cisternal lavage with urokinase and nimodipine after aneurysmal subarachnoid hemorrhage
2024-517798-25-00Phase 2Authorised
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Nov 2024
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of urokinase and nimodipine in subarachnoid hemorrhage (SAH) (2 arms), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Favorable neurological outcome at 6 months. Planned start Nov 2024; status: authorised.
02
Drugs
urokinasenimodipine
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2024-517798-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517798-25-00.